Part 4 of our series, "Understanding INET."
This article is educational in nature and does not replace personalised medical advice. K2F-DIA and K2M-DIA are not substitutes for insulin, and any change to insulin therapy must only ever be made by the treating physician. If you are managing diabetes or any other health condition, please consult a qualified practitioner before making any changes to your treatment.
The third and final pair of INET medicines is the most specialised in the range. K2F-DIA, for women, and K2M-DIA, for men, are compounds developed specifically as adjuvants in the treatment of Type 1, insulin-dependent diabetes — built on the same neuroendocrine foundation as K2F and K2M, but adapted with the pancreatic loculus specifically in mind.
What Changes From the Basic Structure
K2F-DIA and K2M-DIA carry across the familiar INET backbone — Glandula pinealis suis, Melatonin, Hypophysis suis, Hypothalamus suis, Glandula thyreoidea suis, and the sex-specific glandular preparations. Two things are added specifically for this formula. The first is an expanded Pancreas suis presence, given across three potencies (D6, D12 and 200K) rather than the single dilution used elsewhere in the range, alongside Hepar suis, Cor suis and Pulmo suis at 200K. GUNA selected liver, heart and lung tissue here for their role in the energy regulation of the pancreatic loculus, following the law of the Five Energy Movements of Acupuncture as described by Nguyen Van Nghi.
The second addition is a trio of oligoelements: Cobaltum gluconicum, Zincum gluconicum and Niccolum gluconicum, each at D6. Zinc, nickel and cobalt form what GUNA describes as the classic core of INET trace-element support, added here specifically for their relevance to pancreatic and metabolic function.
"They are compounds used as adjuvants in the treatment of Type 1 (Insulin-dependent) Diabetes."
An Adjunct, Never a Replacement
This is the single most important thing to understand about K2F-DIA and K2M-DIA: GUNA's own literature is explicit that they are not substitutes for insulin. Insulin therapy should continue exactly as prescribed, and any adjustment to dosing must always be made by the treating physician, based on that physician's own monitoring of glycaemic levels — never adjusted independently on the basis of a supplementary remedy.
GUNA's stated scope of application for K2F-DIA and K2M-DIA is also narrower than for the rest of the INET range: it is limited specifically to cases of Type 1 diabetes where physiopathological conditions of recent and partial autoimmune damage have been confirmed, rather than diabetes in general.
What GUNA's Own Clinical Reports Describe
GUNA's literature includes clinical observations, gathered under close medical supervision, of children with Type 1 diabetes who used K2F-DIA or K2M-DIA alongside their prescribed insulin therapy, with insulin dosing adjusted gradually over time by the treating physician in response to ongoing glycaemic monitoring. We are deliberately not reproducing the specific figures or timelines from those reports here: they describe individual cases followed intensively by a single clinical team under hospital-linked paediatric supervision, and are not a guide for what any individual should expect or attempt on their own. GUNA itself notes that this area of its research was, at the time of writing, still at a delicate and early stage, with formal registration of the therapy still in progress.
If you or a family member are managing Type 1 diabetes and are curious about K2F-DIA or K2M-DIA, the right first step is a conversation with the treating physician or diabetes care team — not a change to insulin dosing based on anything read here or elsewhere.
Dosage
Where used, the standard posology is 10 drops, two to three times a day, not exceeding a maximum daily dose of 30 drops — always alongside, never instead of, prescribed insulin therapy.
The Series in Summary
Across this series we have traced INET from its roots in Reckeweg's homotoxicology, through the PNEI research that reframed the endocrine, immune and nervous systems as a single interconnected network, to the three product groups built on that foundation: K2F and K2M restoring the basic integrity of the neuroendocrine axis, Senectus F and Senectus M adapting that same foundation for the physiology of ageing, and K2F-DIA and K2M-DIA extending it, cautiously and always as an adjunct, into the management of Type 1 diabetes. What ties all three groups together is the same underlying premise: that supporting the neuroendocrine axis directly, alongside whatever other therapy a person is already receiving, gives the body's own regulatory systems a better foundation to work from.
Featured products
Guna K2F DIA
Adjunct neuroendocrine support for women with Type 1 diabetes.
Explore the full Guna Endocrinology range — INET compounds and neuroendocrine support built on GUNA’s PNEI research.
Not sure which remedy is right for you?
Try our Natural Remedy Finder, or contact our team for guidance.
Related reading
- Senectus F and Senectus M: Supporting Healthy Ageing
- K2F and K2M: Restarting the Neuroendocrine Axis
- What Is INET? From Homotoxicology to Integrated Neuro Endocrine Therapy
Source: GUNA, *From Homotoxicology to INET*, "The Tertiary Group of Medicines — K2F-DIA and K2M-DIA," and "Clinical Cases" by Salvatore Matarese, M.D.
Tags: Guna Articles, Understanding INET, K2F-DIA, K2M-DIA, Diabetes Support